STOCK TITAN

Helius Medical Technologies, Inc. - $HSDT STOCK NEWS

Welcome to our dedicated page for Helius Medical Technologies news (Ticker: $HSDT), a resource for investors and traders seeking the latest updates and insights on Helius Medical Technologies stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Helius Medical Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Helius Medical Technologies's position in the market.

Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) achieves a significant milestone with CMS assigning HCPCS Level II codes for PoNS Therapy for MS patients, extending cash runway with recent stock issuances. The company anticipates reimbursement negotiations with third-party payers and potential positive cash flow post-reimbursement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.19%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. announces FDA interaction and clinical program optimization for PoNS Therapy in stroke patients. The company aims to evaluate non-invasive neuromodulation for gait and balance deficits, targeting regulatory submission and marketing authorization by 2025. Real-world evidence demonstrates significant improvement in gait and balance, positioning the company for potential breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. expands its presence at the 2024 American Physical Therapy Association (APTA) Combined Sections Meeting to showcase its Portable Neuromodulation Stimulator (PoNS®) and highlight the role of physical therapists in using the therapy to improve gait in people with multiple sclerosis (MS). PoNS-trained physical therapists are now present in 10 states across the US, including those with the highest MS prevalence such as New York, California, and Florida.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) expands registrational program for PoNS Therapy™ with the addition of Brooks Rehabilitation Hospital, bringing the total number of patients to 100. The study focuses on evaluating cranial-nerve non-invasive neuromodulation for gait/balance deficits in chronic stroke survivors, with the goal of achieving U.S. authorization under PoNS’s breakthrough designation for stroke.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (HSDT) to present at NobleCon 19th Annual Emerging Growth Equity Conference. President and CEO Dane Andreeff to discuss novel therapeutic neuromodulation approach for balance and gait deficits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announces Q3 2023 results, with $143 thousand in revenue, a decrease from Q3 2022, and operating cash burn of $2.5 million. The company extended its cash runway into Q2 2024, and received UPC numbers for the PoNS system and mouthpiece, allowing for dual paths of reimbursement. A letter of intent from the Québec Ministry of Health and Social Services for the purchase of up to 30 PoNS systems was also received.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
Rhea-AI Summary
Helius Medical Technologies has announced the publication of a white paper demonstrating that rehabilitative treatment with the Portable Neuromodulation Stimulator (PoNS) can significantly improve return-to-work outcomes for patients suffering from traumatic brain injury (TBI). The study, co-sponsored by Pacific Blue Cross and HealthTech Connex, showed that 56% of participants who were previously unable to work due to TBI returned to their prior occupations after 14 weeks of PoNS Therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
none
-
Rhea-AI Summary
Helius Medical Technologies, Inc. expects to report Q3 revenues between $140,000 and $150,000 due to the conclusion of the Patient Therapy Access Program. They also anticipate having approximately $7.0 million in cash and extending their cash runway into Q2 2024. The company will release its Q3 2023 financial results on November 9, 2023, and will host a conference call to discuss the results and provide an update on their progress and plans for the U.S. commercialization of PoNS®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
-
Rhea-AI Summary
Helius Medical Technologies receives letter of intent from Québec Ministry of Health and Social Services for purchase of 30 PoNS devices
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
Rhea-AI Summary
Helius Medical Technologies CFO to participate in upcoming conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
Helius Medical Technologies, Inc.

Nasdaq:HSDT

HSDT Rankings

HSDT Stock Data

2.36M
829.47k
0.85%
11.59%
8.14%
Electromedical and Electrotherapeutic Apparatus Manufacturing
Manufacturing
Link
United States of America
NEWTOWN

About HSDT

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.